Overview

PPARs are binding-dependent transcription factors that regulate gene expression by specifically binding to PPAR response elements. By activating the transcription of these target genes, PPAR plays a role in the regulation of glucose homeostasis, cell differentiation, lipid metabolism, and in obesity and cancer. Studies have identified altered PPAR expression in diet-induced obesity. Considering its location at the intersection of several metabolic pathways and its impact on mitochondrial function, and obesity, researchers are interested in the prospect of targeting PPAR for anti-obesity therapies. Protheragen offers a customized PPAR-targeting anti-obesity therapy development service.

Unlock New Anti-Obesity Therapies with Our Service

We provide one-stop research services from drug design and computer simulation to in vitro and in vivo anti-obesity studies. We have a combination of computational software methods and molecular databases to accelerate the process of anti-obesity drug development and research targeting PPAR. Specific services include the following:

Anti-Obesity Drug Development

PPAR activity is finely regulated by a variety of compounds. Natural and synthetic PPAR modulators have been found to have great potential in the treatment of obesity and its associated complications. We screen PPAR modulators by modification of known structures or high throughput screening. These molecules are expected to be highly effective drugs for the treatment of obesity. There are three different genetically encoded isoforms of PPAR (PPARα, PPARγ, PPARβ/δ). PPARα is involved in lipid metabolism and is highly expressed in muscle, heart, and liver. PPARγ is mainly expressed in brown and white adipose tissues and is responsible for adipogenesis. PPARβ/δ plays a role in energy regulation and fatty acid oxidation. We develop anti-obesity drugs targeting these three receptors.

• PPARα: It is involved in the regulation of key genes in lipid transport and fatty acid oxidation. We synthesize PPARα agonists and evaluate their pharmacological properties. In addition to this, we screen natural PPARα agonists such as phenylpropanoids, polyphenols, terpenes, alkaloids, polyketides, and other extracts.
• PPARγ: It regulates cell proliferation, adipogenesis, and lipid metabolism. Abnormal PPARγ signaling is associated with obesity and other diseases. We consider the multiple docking sites of PPARγ, molecular docking, structure-activity relationship, the pleiotropy of its signaling, and design PPARγ agonists. PPARγ agonists are designed to regulate PPARγ signaling and ultimately exert anti-obesity effects.
• PPARβ/δ: PPARβ/δ partial agonists show great potential in improving insulin sensitivity and inhibiting fatty acid oxidation. We combine multiple cutting-edge technologies to evaluate the role of PPARβ/δ partial agonists in the treatment of obesity.
• Others: In addition to these, we screen and synthesize dual agonists (PPARα/γ dual agonists, PPARα/δ dual agonists, PPARγ/δ dual agonists) and PPARα/γ/δ full agonists. Their potential in the treatment of obesity is also assessed.

Preclinical Studies for Anti-Obesity Therapies

Our advanced bioinformatics analysis team performs molecular dynamics simulations and molecular docking analysis through various advanced algorithms to understand the binding affinity of PPAR agonists. In addition to this, we also assess the anti-obesity potential of PPAR agonists through in vivo and in vitro experiments.

• In vitro studies: We culture adipocytes and use these in vitro cultured cells to validate the cytotoxicity and anti-obesity effects of natural and synthetic PPAR agonists.
• In vivo studies: We construct a variety of in vivo obesity animal models and study the effects of natural and synthetic PPAR agonist administration on them. We are familiar with multiple routes of administration and assess their pharmacodynamics (PD), pharmacokinetics (PK), bioanalysis, and safety through comprehensive analyses.

Workflow

Our experienced researchers provide a one-stop service for the development of anti-obesity therapies targeting PPAR, based on their in-depth studies of obesity pathogenesis and anti-obesity therapies.

Applications

• Metabolic diseases research: PPAR activators have some metabolic modulating activity. Anti-obesity therapies targeting PPAR provide valuable information for research on therapeutic approaches to metabolic diseases.
• Diabetes research: PPAR modulators are a promising approach for the treatment of diabetes. Potential anti-obesity drugs targeting PPAR provide new insights into the design and development of novel diabetes drugs.
• Cancer research: Anti-obesity therapies targeting PPAR also have potential applications in the treatment of cancer.

Advantages

• Customized PPAR-targeted anti-obesity therapeutic development services: We provide customized solutions including PPAR-targeted anti-obesity drug design, synthesis, and preclinical validation to meet the different needs of various research projects.
• Powerful and scalable technologies: Based on years of profound research, we have a variety of cutting-edge technologies to support the development of anti-obesity therapies targeting PPAR.
• Experienced scientific team: Our team of scientists has many years of experience in obesity mechanisms and therapy development. They provide technical support in every process of anti-obesity therapy development.

Our Services and Innovative Solutions

We are at the forefront of obesity research and treatment development and are committed to providing our clients with the best possible research services using personalized solutions. Based on an experienced team, we provide comprehensive obesity-related analysis and testing services and delve into the multifaceted root causes of obesity, such as genetic, environmental, and metabolic factors. In addition to this, we offer advanced diagnostic testing and obesity prediction services. Obesity biomarker analysis, obesity-related gene editing, microbiome, and pathobiology studies are our areas of expertise. We also provide specialized weight loss and management services to help with scientific monitoring and management.

Publication

Frequently Asked Questions

Which natural products modulate PPAR?

PPAR is a novel therapeutic target for treating obesity and related diseases. Various natural products have been identified as PPAR modulators, such as terpenes, polyketide compounds, phenylpropanoids, polyphenols, alkaloids, and other extracts.

• Terpenes: Monoterpenes, sesquiterpenes, diterpenes, triterpene compounds, etc., are potential PPAR modulators with the potential to treat obesity.
• Polyphenols: Flavonoids and others reverse PPAR dysfunction thereby exerting anti-obesity effects.
• Alkaloids: Some alkaloids are potential PPAR modulators and have a certain degree of weight loss, lowering blood sugar to reduce impaired glucose tolerance.
• Other extracts: Polyketides, phenylpropanoids, etc., also modulate PPAR. Several total extracts have been found to modulate PPAR α activity and positively affect lipid and metabolic abnormalities.

What is the cost of anti-obesity therapy services targeting PPAR?

The cost of PPAR-targeted anti-obesity therapy services varies widely depending on what is included in the service, such as screening and synthesis of the drug, computerized analyses, and in vitro and in vivo preclinical studies.

Protheragen has world-class expertise and uses this expertise to provide customized solutions for your anti-obesity therapies targeting PPAR. Welcome to contact us to discuss your research project in detail with our experts. We will advise on the best experimental protocol and provide reliable support.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

• Targeting Cannabinoid Receptors (CB1 and CB2) for Developing Anti-Obesity Therapeutics
• Targeting Gastric Inhibitory Polypeptide (GIP) Receptor for Developing Anti-Obesity Therapeutics
• Targeting Glucagon Receptor (GCGR) for Developing Anti-Obesity Therapeutics
• Targeting Melanocortin 4 Receptor (MC4R) for Developing Anti-Obesity Therapeutics
• Targeting Orexin Receptors (OX-1 and OX-2) for Developing Anti-Obesity Therapeutics
• Targeting Serotonin (5-HT) Receptors for Developing Anti-Obesity Therapeutics
• Targeting Sodium-Glucose Cotransporter for Developing Anti-Obesity Therapeutics